UK's Hikma Pharmaceuticals reiterates 2026 outlook despite higher costs from Iran war

Hikma Pharmaceuticals reiterated ​its 2026 ‌guidance on Thursday, adding ​that, while ​it has faced ⁠some pressure ​on shipping, ​energy, and insurance costs due ​to the ​war in the ‌Middle ⁠East, a key market for the ​firm, ​it ⁠was confident it ​could ​absorb ⁠the higher costs.